This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00411749
First received: December 14, 2006
Last updated: March 23, 2017
Last verified: March 2017
  Purpose
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females

Condition Intervention Phase
HPV Infections Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501) Biological: Comparator: Placebo (unspecified) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Investigator
Primary Purpose: Prevention
Official Title: V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Human Papilloma Virus (HPV) 6 Serum Antibody Titer at One Month After Completed Vaccination Series [ Time Frame: At one month after completed vaccination series (Month 7) ]

    Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers (GMT) by vaccine group.

    The limit of detection of the assay was 7 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "7.0".


  • Human Papilloma Virus (HPV) 11 Serum Antibody Titer at One Month After Completed Vaccination Series [ Time Frame: At one month after completed vaccination series (Month 7) ]

    Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.

    The limit of detection of the assay was 8 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "8.0".


  • Human Papilloma Virus (HPV) 16 Serum Antibody Titer at One Month After Completed Vaccination Series [ Time Frame: At one month after completed vaccination series (Month 7) ]

    Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.

    The limit of detection of the assay was 11 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "11.0".


  • Human Papilloma Virus (HPV) 18 Serum Antibody Titer at One Month After Completed Vaccination Series [ Time Frame: At one month after completed vaccination series (Month 7) ]

    Month 7 HPV Competitive Luminex immunoassay (cLIA) Geometric Mean Titers by vaccine group.

    The limit of detection of the assay was 10 mMU/ml. GMTs and confidence limits below the limit of detection are shown as "10.0".



Secondary Outcome Measures:
  • HPV 6, 11, 16 and 18 Serum Antibody Titer at 24 Month After Completed Vaccination Series [ Time Frame: 24 month after completed vaccination series (Month 30) ]
    Month 30 HPV cLIA Geometric Mean Titers by vaccine group.


Enrollment: 107
Actual Study Start Date: December 11, 2006
Study Completion Date: September 18, 2009
Primary Completion Date: September 18, 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: V501

V501 vaccination Quadrivalent HPV (Types 6, 11, 16,

18) L1 VLP Vaccine Injection

cervix cancer exgenlesion Vaccination at Day 1, Month 2, and Month 6. Total 3 vaccinations. 0.5 mL intramuscular dose of V501 (HPV L1 Virus-Like Particle [VLP] Type 6,

Type 11, Type 16, Type 18) or placebo at Day 1, Month 2 and Month 6.

Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)
V501; Gardasil, 0.5 ml injection in 3 dosing regimen
Other Names:
  • V501
  • Gardasil
Placebo Comparator: Placebo
Placebo vaccination, Placebo 0.5 ml injection in 3 dosing regimen
Biological: Comparator: Placebo (unspecified)
Placebo 0.5 ml injection in 3 dosing regimen

  Eligibility

Ages Eligible for Study:   9 Years to 17 Years   (Child)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Virginal Female Subject Aged 9 To 17 Years

Exclusion Criteria:

  • Male Subject
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00411749

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00411749     History of Changes
Other Study ID Numbers: V501-028
2006_052
Study First Received: December 14, 2006
Results First Received: July 19, 2010
Last Updated: March 23, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description:

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php


Additional relevant MeSH terms:
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017